- Home
- HSHP vs AQST Comparison
HSHP vs AQST Comparison
Compare HSHP & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSHP
- AQST
- Stock Information
- Founded
- HSHP 2021
- AQST 2004
- Country
- HSHP Bermuda
- AQST United States
- Employees
- HSHP N/A
- AQST N/A
- Industry
- HSHP
- AQST Biotechnology: Pharmaceutical Preparations
- Sector
- HSHP
- AQST Health Care
- Exchange
- HSHP Nasdaq
- AQST Nasdaq
- Market Cap
- HSHP 248.0M
- AQST 274.4M
- IPO Year
- HSHP 2023
- AQST 2018
- Fundamental
- Price
- HSHP $5.46
- AQST $2.86
- Analyst Decision
- HSHP
- AQST Strong Buy
- Analyst Count
- HSHP 0
- AQST 7
- Target Price
- HSHP N/A
- AQST $10.57
- AVG Volume (30 Days)
- HSHP 176.5K
- AQST 1.3M
- Earning Date
- HSHP 05-20-2025
- AQST 03-05-2025
- Dividend Yield
- HSHP 8.37%
- AQST N/A
- EPS Growth
- HSHP 1123.58
- AQST N/A
- EPS
- HSHP 0.48
- AQST N/A
- Revenue
- HSHP $123,580,000.00
- AQST $57,561,000.00
- Revenue This Year
- HSHP $11.04
- AQST N/A
- Revenue Next Year
- HSHP $26.01
- AQST $39.51
- P/E Ratio
- HSHP $12.28
- AQST N/A
- Revenue Growth
- HSHP 236.40
- AQST 13.79
- 52 Week Low
- HSHP $4.48
- AQST $2.24
- 52 Week High
- HSHP $9.76
- AQST $5.80
- Technical
- Relative Strength Index (RSI)
- HSHP 45.02
- AQST 45.84
- Support Level
- HSHP $5.70
- AQST $3.05
- Resistance Level
- HSHP $5.96
- AQST $3.24
- Average True Range (ATR)
- HSHP 0.16
- AQST 0.19
- MACD
- HSHP -0.06
- AQST 0.01
- Stochastic Oscillator
- HSHP 8.21
- AQST 22.06
About HSHP Himalaya Shipping Ltd.
Himalaya Shipping Ltd is an independent dry bulk company that focuses on owning and operating its Newcastlemax dry bulk carriers.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States.